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INTRODUCTION
About two-thirds of outpatients with current 
anxiety and/or depressive disorder(s) 
receive psychopharmacological treatment, 
most notably antidepressants.1 Often, 
antidepressant use is long term. For 
example, in the Netherlands approximately 
30% of patients taking antidepressants take 
them for >1 year.2 Similarly, in the UK nearly 
half of the patients taking antidepressants 
take them for >2 years,3,4 and in the US 
this is true for approximately two-thirds of 
relevant patients.5,6 
Moreover, only 10% of such patients 
discontinue antidepressants each year.7 This 
is contrary to the consensus-based advice of 
the international and UK guidelines, which 
recommend discussing discontinuation 
of antidepressants 6–18 months after 
remission for anxiety disorders8–11 and 
4–12 months for depressive disorders.12–15 
Long-term use is advised only in case 
of chronicity or for patients who have 
experienced high recurrence rates.8,12,14 
Patients need tailored treatment plans 
based on these guidelines. Unnecessary 
continuation of antidepressants may result 
in long-term side effects16 and substantial 
healthcare costs.17,18
Comparatively little is known about 
the motivations of patients to continue or 
discontinue antidepressants. Research 
indicates that patients tend to experience 
their long-term use as problematic, but 
also foresee problems with discontinuation 
(for example, withdrawal or relapse).19,20 
Furthermore, some GPs discuss 
antidepressant continuation with patients, 
but also fear the consequences of 
discontinuation.21
To gain insight into possibilities to prevent 
unnecessary long-term antidepressant use, 
the motivations and barriers of patients 
and GPs to continue or discontinue 
antidepressants were assessed. In-depth 
interviews were conducted with patients 
with anxiety and/or depressive disorder(s) 
who had been using antidepressants for 
>6 months, and with their GPs. 
Extending previous research, the 
interplay between patients and their GPs 




Recruited participants were patients with 




Antidepressant use is often prolonged in 
patients with anxiety and/or depressive 
disorder(s) compared with recommendations 
in treatment guidelines to discontinue after 
sustained remission.
Aim
To unravel the motivations of patients and 
GPs causing long-term antidepressant use 
and to gain insight into possibilities to prevent 
unnecessary long-term use.
Design and setting
Qualitative study using semi-structured, 
in-depth interviews with patients and GPs in the 
Netherlands.
Method
Patients with anxiety and/or depressive 
disorder(s) (n = 38) and GPs (n = 26) were 
interviewed. Innovatively, the interplay between 
patients and their GPs was also investigated by 
means of patient–GP dyads (n = 20).
Results
The motives and barriers of patients and GPs 
to continue or discontinue antidepressants 
were related to the availability of supportive 
guidance during discontinuation, the 
personal circumstances of the patient, and 
considerations of the patient or GP. Importantly, 
dyads indicated a large variation in policies 
of general practices around long-term 
use and continuation or discontinuation of 
antidepressants. Dyads further indicated that 
patients and GPs seemed unaware of each 
other’s (mismatching) expectations regarding 
responsibility to initiate discussing continuation 
or discontinuation. 
Conclusion
Although motives and barriers to 
antidepressant continuation or discontinuation 
were related to the same themes for patients 
and GPs, dyads indicated discrepancies 
between them. Discussion between patients 
and GPs about antidepressant use and 
continuation or discontinuation may help clarify 
mutual expectations and opinions. Agreements 
between a patient and their GP can be included 
in a patient-tailored treatment plan.
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GPs. To examine patient–GP dyads, part of 
the sample included patients (n = 30 out of 
38) with their own GP (n = 20 out of 26).
GPs were approached by telephone and 
e-mail via the recruited patients or via the 
GP network affiliated with the VU University 
Medical Center Amsterdam (VUmc) and 
University Medical Center Groningen, in 
the Netherlands. When GPs agreed to 
participate, they were asked to contact one 
to two eligible patients.
Patients were recruited via websites 
of patient associations for anxiety and 
depression (Fonds Psychische Gezondheid 
[the Netherlands Foundation for Mental 
Health] and Depressie Vereniging 
[Depression Association]); and via 
participating GPs. Inclusion criteria were: 
• having an antidepressant prescribed for 
anxiety and/or depressive disorder(s). 
This was based on the self-report of 
the patient, but wherever possible the 
diagnosis was verified with the GP; 
• antidepressant use for >6 months;
• antidepressant prescriptions by the GP; 
• patient is in remission from their 
anxiety and/or depressive disorder(s) 
(although not formally checked with a 
diagnostic interview, patients were asked 
about remaining symptoms and GPs 
were asked to only contact patients in 
remission);
• age ≥18 years; and
• sufficiently fluent in Dutch.
The research team contacted interested 
patients and GPs, and provided them with 
additional information.
Data collection and analysis
In-depth, semi-structured interviews were 
conducted between October 2014 and June 
2015. All patients were interviewed at home, 
except one patient who was interviewed 
at the GP’s practice. Patients were never 
present during the GP interviews and vice 
versa. Dyads were discussed depending 
on the focus of the interview and available 
time. Four master students conducted the 
interviews, they studied clinical psychology or 
medicine and received interview training and 
supervision from one of the study authors. 
They were unrelated to the participants.
Interviews with patients had a 
mean duration of 49 ± 17 minutes 
(range 24–106 minutes) and with GPs 
45 ± 10 minutes (range 28–90 minutes). 
Interviews were audiotaped and transcribed 
verbatim. Participants did not comment on 
the transcripts and no repeat interviews 
were conducted. A topic list guided the 
interviews (Appendices 1 and 2). This list 
was based on themes extracted from the 
literature; listed phone enquiries made 
by patients at patient associations for 
anxiety and depression; and discussions 
by the research team based on their 
multidisciplinary clinical experience.
Analysis was based on the constant 
comparative method,22 implying an iterative 
process of data analysis and planning of 
interviews. This allows for updating the 
topic list in the light of emerging themes 
(Appendices 1 and 2) and maximises 
knowledge about participants’ considerations. 
By searching for new topics and testing 
predetermined topics, this method is both 
inductive and deductive, and fits with an 
instrumental-pragmatic approach.23
Interviews were analysed in Dutch 
using MAXQDA software for qualitative 
data analysis (version 10); the authors 
translated the quotes into English. Two 
interviewers coded the first two interviews 
independently, codes were then compared, 
and consensus was reached about an 
initial framework. Analysis was continued 
by updating the coding framework after 
every two interviews and at research group 
meetings. Data collection ended when data 
were saturated; that is, the information was 
repeating itself and no new information 
was added based on four new interviews. 
To analyse dyads, interview parts in which 
the patient spoke about their GP and vice 
versa were coded separately, specifically 
focusing on the patient–GP interplay. Dyads 
were analysed in R (version 3.2.0) using the 
RQDA package (version 0.2-7). This method 
was checked using the COREQ checklist.24
RESULTS
Demographics
Demographic and clinical characteristics 
of the patients (n = 38) and GPs (n = 26) are 
How this fits in
Contrary to guidelines, long-term use of 
antidepressants is common in patients 
with anxiety and/or depressive disorder(s). 
This study provides insight into the 
motives and barriers of patients and 
GPs to antidepressant continuation and 
discontinuation. Additionally, patient–GP 
dyads provide insight into the interplay 
between them and their mismatching 
expectations. This study highlights the 
importance of discussion on antidepressant 
use between patients and GPs to clarify 
mutual expectations and determine long-
term treatment plans.
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provided in Table 1. This sample contained 
30 patient–GP dyads. In 10 dyads, either the 
patient or the GP did not mention the other 
person, thus 20 dyads could be analysed, 
including 20 patients and 14 GPs.
Dyads
Dyads showed that, although GPs 
consider themselves suitable to provide 
supportive guidance during discontinuation, 
patients did not necessarily agree. In the 
perception of patients, GPs sometimes 
lacked knowledge and time, and had many 
competing demands:
‘I think that the GP knows a lot, but only 
little bits. They only have basic knowledge 
about many areas. I do not blame them for 
that, but I do have more faith in the experts. I 
think that the GP should refer me sooner to 
specialised care, because they cannot know 
everything.’ (Patient, female, 44 years)
‘I think that I am capable of providing 
Table 1. Demographic and clinical characteristics of patients’ and GPs’ total sample, and for patient–GP 
dyads separately
 Total, n Dyads, n
 Patient GP Patient GP 
 (n = 38) (n = 26) (n = 20) (n = 14)
Age range, years 30–68 30–64 30–68 30–59 
 30–39 8 3 4 2 
 40–49 8 8 5 4 
 50–59 15 11 7 8 
 ≥60 7 4 4 0
Sex 
 Female 28 15 15 8 
 Male 10 11 5 6
Area 
 Rural 18 8 8 5 
 Urban 20 18 12 9
Ethnic group  NA  NA 
 West European 37  19 
 Non-West European 1  1
Diagnosis  na  na 
 Anxiety disorder 11  8 
 Depressive disorder 21  10 
 Anxiety and depressive disorder 6  2
Antidepressant  na  na 
 SSRIa 26  11 
 SNRIb 10  8 
 TCA 2  1
Experience with discontinuation?c  na  na 
 Yes, but restarted because of relapse/recurrence 29  16 
 Yes, but never completely discontinued because of relapse/recurrence 3  1 
 No 6  3
Duration of antidepressant treatment, yearsd  na  na 
 1–4 7  3 
 5–9 8  6 
 10–14 7  2 
 15–19 10  7 
 >19 6  2
Recruited via 
 GP 20 na 12 na 
 Patient association 18 na 8 na 
 Patient na 10 na 8 
 GP network na 16 na 6 
aWith the addition of an atypical antipsychotic (n = 1), methylphenidate (n = 1), or a noradrenergic and specific serotonergic antidepressant (n = 1). bWith the addition of 
lithium (n = 1). cAvailable information regarding relapse/recurrence of episodes is insufficiently detailed to differentiate between relapse and recurrence. dMost patients using 
antidepressants for 1–4 years continuously used antidepressants, whereas patients using antidepressants for ≥5 years mostly attempted to discontinue, or discontinued 
and restarted. na = not applicable. NA = not available. SNRI = serotonin norepinephrine reuptake inhibitor. SSRI = selective serotonin reuptake inhibitor. TCA = tricyclic 
antidepressant. 
e710  British Journal of General Practice, October 2016
supportive guidance to patients who are 
discontinuing antidepressants.’ (GP, male, 
49 years)
Dyads also indicated discrepancies 
between the patient’s need of care and the 
GP’s options to meet this. Some patients 
indicated that they need at least 1 hour a 
week of support during discontinuation, 
whereas their GP suggested that a 
consultation lasting 10–20 minutes once 
a week or once every fortnight would be 
sufficient. In the Netherlands a consultation 
covered by health insurance has a 
duration of 10 minutes, but if there is a 
need a consultation can be extended to a 
‘double consultation’, lasting 20 minutes. 
Consultations with a duration of >20 minutes 
are not covered by health insurance. The 
mean duration of a GP consultation in the 
Netherlands is 13 minutes.25
Moreover, dyads showed that, although 
most patients and GPs had contact about 
antidepressant use, policies around long-
term use and continuation or discontinuation 
varied largely. Some patients saw their GP 
multiple times a year, but these contacts 
were not necessarily about antidepressant 
continuation or discontinuation. When 
patients came for other complaints, 
antidepressant use was discussed too. One 
practice, however, specifically checked long-
term users of antidepressants on a yearly 
basis: 
‘I need to visit the GP once a year anyway for 
my diabetes check-up. We see each other 
at that moment anyway, and then we also 
tend to discuss my antidepressant use.’ 
(Patient, female, 58 years)
‘We evaluate at least once a year, standard 
for patients taking antidepressants or … 
there is also other medication which we 
also evaluate every year. Normally these 
are short appointments, but at least we 
keep track of the patients. Not willing to 
discontinue yet? Fine, but at least we know.’ 
(GP, female, 35 years) 
Dyads further indicated that it is unclear 
who is responsible for initiating contact 
about antidepressant continuation or 
discontinuation. Patients said they tend to 
initiate contact with the GP about their wish 
to discontinue, but think that the GP should 
take this responsibility:
‘I do think that the GP is responsible for his 
patient, and should therefore also take the 
initiative around antidepressant treatment. 
On the other hand, there is also a trend 
towards that you need to sort out yourself. 
I think that both patient and GP should 
be involved, but when you are depressed 
you haven’t got the opportunities nor the 
insight to do anything. So in that respect the 
GP should take the responsibility.’ (Patient, 
female, 44 years)
On the contrary, some GPs stated that 
when a patient is stable on medication 
there is no need for follow-up. They expect 
patients to contact them when their 
situation changes or when the patient wants 
to change or discontinue their treatment.
Supportive guidance
Patients and GPs agreed about who 
should provide supportive guidance 
during discontinuation: namely the GPs 
themselves, mental health assistants, or 
psychiatrists or psychologists. Both patients 
and GPs indicated that people in their social 
environment (for example, relatives or 
friends) can also help with monitoring. One 
GP indicated that these people can also 
provide supportive guidance.
Several conditions applied to 
discontinuation. Some patients needed 
information about discontinuation effects. 
Both groups indicated that discontinuation 
schedules or modules can be useful, and 
that medication should be tapered when 
discontinued. Further, three GPs indicated 
that treatment guidelines should provide 
more information on how to discontinue:
‘What you tend to regularly do is check 
the treatment guidelines, also when you 
are prescribing medication. A heading 
“discontinuation: what do you need to do?” 
could for example be included. I did not 
check, but do not think that currently exists.’ 
(GP, female, 41 years)
A small numbers of patients and GPs 
(four patients and two GPs) indicated that, 
after patients completely discontinued their 
medication, supportive contacts should be 
maintained, also to monitor symptomatology. 
For both groups, the preferred frequency of 
this contact varied from once a month to four 
times a year.
Importantly, some patients and GPs 
mentioned that continuation could also 
result from ignorance or neglect. Taking 
antidepressants can be incorporated into a 
patient’s daily routine, without questioning. 
Further, GPs may also lose track of patients 
and their use of antidepressants. Some GPs 
prefer an automatic warning when they 
authorise repeat prescriptions for a patient 
who is potentially eligible for discontinuation:
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‘Sometimes you are just very busy and you 
think “let’s get those repeat prescriptions 
over and done with”, other times you have 
more time and you wonder “how long is 
this patient already using this or when did 
I last see this patient”. So it depends a bit. 
If someone asked for a repeat prescription 
once every 3 months and you authorise the 
prescription on a day that you are extremely 
busy, then you may not notice.’ (GP, female, 
51 years)
Personal circumstances
The patient’s improved functioning was a 
reason to continue as well as to discontinue 
antidepressants for patients and GPs:
‘I am so glad that this patient is doing so 
much better, so we are both less inclined to 
discontinue.’ (GP, male, 57 years)
‘I had been well for a long time. Then I was 
thinking why … I could try to discontinue, it 
is poison anyway. You also don’t take pain 
killers when you do not need them, so 
why continue taking antidepressants? Or 
let’s put it differently, why not attempt to 
discontinue when you have been well for a 
long time?  ’ (Patient, male, 54 years)
For both, side effects were an important 
reason for discontinuation. According to 
some patients and several GPs the correct 
conditions for discontinuation were that 
the patients’ personal circumstances were 
stable, the number of stressful situations 
limited, and the patient is motivated (exact 
numbers for reasons for discontinuation 
are: personal circumstances stable — five 
patients and 10 GPs; a limited number of 
stressful situations — two patients and two 
GPs; patient motivated to discontinue — two 
patients and nine GPs):
‘When I have agreed with a patient that 
we are going to discontinue in 6 months’ 
time and just before, a major life event 
occurs then that is not the right moment 
for discontinuation. You need to wait a bit, 
sometimes just 2 months and then it is 
possible.’ (GP, female, 57 years)
Even when these conditions were met, 
some patients still continued because they 
did not want to become a burden to their 
social environment:
‘In general the responsibility you do have 
for your family … so even if I wanted to 
discontinue, it does not only affect me but also 
my environment … that makes my decision 
extra difficult.’ (Patient, male, 50 years)
Furthermore, two patients questioned 
whether complete discontinuation should 
be the target or should the medication 
be reduced to a ‘maintenance dose’? 
Moreover, GPs added that the number of 
relapses should be limited (the amount 
of relapses varied between GPs, with a 
minimum of one relapse and a maximum 
of three relapses indicated as a limited 
number), and patients should have faith in 
themselves being able to function without 
the use of antidepressants.
Patient–GP considerations
Patients often viewed antidepressants and 
the taking of them as ‘unnatural’, ‘chemical’, 
or ‘foreign to the body’, that is, ‘unnatural’ 
(six patients), ‘chemical’ (nine patients), 
or ‘foreign to the body’ (five patients); 16 
individual patients used at least one of 
these descriptions and therefore wished 
to discontinue. One GP also described 
antidepressants as ‘chemical’ and provided 
this as a reason for discontinuation. Further, 
about half of the patients wished to be self-
reliant:
 
‘I have got a very strong drive to be healthy 
again. Taking medication has the same 
meaning to me as it had at the time. 
Although I am feeling well, there is still 
something in my head telling me that only 
when I discontinue my medication, I am 
really well again.’ (Patient, female, 32 years) 
Some patients wanted to discontinue 
because of perceived (physical) dependency:
‘I think it is addictive because you have to 
start and discontinue really slowly. You can 
also really feel it when you discontinue. I 
find it quite scary, I dislike it, but should not 
think about it too much. That is why I try to 
take as little as possible, because I think 
“just imagine that it is addictive”. It just does 
not feel right.’ (Patient, female, 49 years)
Although patients tended to perceive 
antidepressants in a negative manner, nearly 
half of them believed that their disorder 
stemmed from a biological cause and 
therefore wished to continue their medication, 
whereas a few GPs shared this belief (for both 
anxiety or depressive disorder):
‘I am really missing something [in my 
brain]. And that is being replaced by an 
antidepressant.’ (Patient, female, 47 years)
Additionally, most of the patients 
(28 of 38) experienced psychological 
treatment in varying extents as helpful, 
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but also considered it insufficient as it 
had not prevented them from relapsing. 
In total, 14 GPs thought that patients can 
become psychologically dependent on 
antidepressants and that this dependency 
may result in continuation: 
‘Patients obviously received antidepressants 
when they were experiencing a miserable 
time. Whether or not it is related to the 
antidepressant, they feel better again 
and link feeling better to having received 
antidepressants. Patients can sometimes 
feel very dependent of those tablets for their 
happiness.’ (GP, female, 50 years)
Furthermore, nearly half of the GPs 
believed that, if possible, patients are 
better off without medication, including 
antidepressants.
Both groups agreed that continuation 
can be a better alternative when a patient 
relapsed after previous discontinuation 
attempts. Additionally, fear of relapse is a 
reason for continuation for over half of the 
patients and GPs even if, as with the patient 
below, continuing with the medication can 
have unwanted side effects:
‘I found side effects, especially a reduction 
of my sex drive, very bothersome. It may 
sound strange, but I would rather have a 
life without depression than a life with a sex 
drive.’ (Patient, male, 60 years)
Some GPs noticed that their patient 
only experienced symptoms in winter and 
therefore saw no indication to continue 
antidepressants during other seasons. 
However, patients continued because of 
discontinuation symptoms and the time 




Dyads indicated discrepancies between 
patients and GPs in the perceived suitability 
of the GP to provide supportive guidance to 
patients; patients and GPs having discrepant 
views on how to meet the perceived 
need of care; large variations between 
practices in patient–GP contact regarding 
antidepressants; and unawareness 
of the different expectations of patients 
and GPs related to who is responsible for 
initiating discussion about antidepressant 
continuation or discontinuation. Further, 
for patients and GPs, the motivations 
and conditions to continue or discontinue 
antidepressants were related to supportive 
guidance during discontinuation, the 
personal circumstances of the patient, and 
underlying considerations.
Strengths and limitations
Because both patients and GPs were 
interviewed about long-term antidepressant 
use, insight was gained into the interplay 
between them and into the motives and 
barriers contributing to continuation or 
discontinuation. Interviewers lived in 
different parts of the Netherlands, therefore 
participants could be sampled across 
rural and urban areas of the Netherlands. 
Patients with anxiety and/or depressive 
disorder(s) using a variety of antidepressants 
were included, and their male:female ratio 
seems to reflect the male:female ratio of 
the common mental disorders.1 
Selection bias cannot be excluded, 
however, as only one patient of non-Western 
European ancestry was included. Moreover, 
original diagnoses were not systematically 
verified for all patients with their GP, and 
patients’ remission state was not based on 
a clinical interview. Nevertheless, GPs were 
asked to refer only patients in remission and 
patients were systematically asked about 
experiencing residual symptoms. Further, 
most patients in this study had relapsed 
previously, which could be a reason for 
continuation. However, discussing their use 
of antidepressants may be helpful, as these 
patients can experience side effects16 and 
diminished functionality.26 Furthermore, 
the four interviewers had limited clinical 
experience and may have missed cues 
for further questioning. However, they 
had received interview training and had 
all conducted a substantial number of 
interviews. Lastly, further research needs to 
determine how widespread the expressed 
opinions are shared within the entire 
population of patients and GPs.
Comparison with existing literature
To date no other studies have investigated 
the interplay between patients and GPs 
regarding long-term antidepressant 
continuation or discontinuation. Dyads 
indicated that GPs perceived they have 
sufficient knowledge and time to provide 
supportive guidance to patients, but 
their patients did not necessarily agree. 
Previous research suggested that GPs 
experience time constraints in the care 
for patients with depressive and/or anxiety 
disorder(s).27 Concurrently, long-term users 
of antidepressants tend to have longer GP 
visits (with a duration of >20 minutes)25 
and they also experience greater social and 
physical limitations than non-users and 
short-term users,28,29 which may also be 
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a consequence of their remaining disease 
burden. When it comes to caring for these 
patients in GP practices, mental health 
assistants could possibly provide more 
support to GPs, for example, by monitoring 
antidepressant use and providing supportive 
guidance during discontinuation.
Furthermore, dyads indicated suboptimal 
communication about antidepressant 
treatment between patients and GPs. 
Patients saw their GP multiple times a year, 
but these meetings were seldom specifically 
about their antidepressant use. Additionally, 
both groups seemed unaware of each 
other’s expectations regarding responsibility 
to discuss continuation or discontinuation. 
Previous research showed that patients 
consider shared decision making to be 
important.19,20 Discussing antidepressant 
continuation or discontinuation can clarify 
mutual opinions and expectations.
Moreover, limited follow-up policies 
may contribute to long-term use, as 
some GPs in this study indicated not 
always having time to evaluate the repeat 
prescriptions. Also in previous studies 
patients mentioned ordering repeat 
prescriptions without discussing them 
with the GP,19,30,31 which is understandable 
practice. Besides, the current treatment 
guidelines are inconclusive about when 
to discontinue antidepressants after 
remission of symptoms,8–15 representing 
consensus rather than evidence-based 
recommendations. Although first steps have 
been made,32 stringent scientific evidence 
regarding relapse risk for individual patients 
is lacking.
The included patients provided several 
reasons for discontinuation; possible 
physical dependency, a negative perception 
of antidepressants and of taking them, and 
concerns around side effects. For these 
patients of whom most had experience 
with discontinuation, however, reasons for 
continuation outweighed the benefits of 
discontinuation. Consistent with existing 
literature, patients continued because of a 
fear of relapse,19,20,33 a perceived biological 
cause for their symptoms,20,29,33 and their 
experience of improved functioning.20,29 
GPs largely agreed with patients on their 
motives for long-term continuation. GPs 
seemed to take a more psychosocial 
than biological perspective, however, on 
continuation or discontinuation,26,33 as they 
indicated conditions for discontinuation 
related to the stability of the social 
environment, the patients’ motivation, and 
their faith in being able to function without 
the use of antidepressants. In accordance 
with the multidisciplinary guidelines,8–15 
GPs were also more inclined to continue 
antidepressants when a patient had 
previously relapsed.
Implications for research and practice
The present results suggest that a more 
definite treatment plan discussed by both 
patient and GP may prevent unnecessary 
long-term use. This long-term plan should 
include agreements about who initiates 
future contact, and the frequency and 
method of this contact. Considerations 
about antidepressant continuation or 
discontinuation can influence treatment 
decisions, therefore GPs should be aware of 
their own and their patients’ considerations 
and discuss them. Furthermore, the GP’s 
mental health assistant could possibly 
have a role in monitoring patients 
using antidepressants, along with the 
implementation of automatic warnings in 
GP prescription systems to bring repeat 
prescriptions to their attention.
Funding
This study was funded by the Netherlands 
Foundation for Mental Health. Henricus 
G Ruhé is supported by an NWO/ZonMW 
VENI-Grant #016.126.059.
Ethical approval
Ethical approval for this study was obtained 
from the Medical Ethical Committee of the 
VU University Medical Center, Amsterdam, 
the Netherlands (reference: 2014.390).
Provenance
Freely submitted; externally peer reviewed.
Competing interests
In the last 5 years, Henricus G Ruhé 
received speaking fees from AstraZeneca 
and Lundbeck NV. Henricus G Ruhé is 
supported by an unrestricted Investigator 
Initiated Trial Grant from Lundbeck NV. 
All the other authors have declared no 
competing interests
Acknowledgements
We would like to thank all patients and GPs 
for their time and willingness to participate 
in this qualitative study. We would also like to 
thank Gyan Peeters, Sabine Polle, Tessa Sol, 
and Joas Zuur for conducting the interviews 
and their enthusiasm for this project. 
Discuss this article
Contribute and read comments about this 
article: bjgp.org/letters
e714  British Journal of General Practice, October 2016
REFERENCES
1. The ESEMeD/MHEDEA 2000 investigators, Alonso J, Angermeyer MC, Bernert 
S, et al. Use of mental health services in Europe: results from the European 
Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta 
Psychiatr Scand 2004; 109(s420): 47–54.
2. Meijer WE, Heerdink ER, Leufkens HG, et al. Incidence and determinants of 
long-term use of antidepressants. Eur J Clin Pharmacol 2004; 60(1): 57–61.
3. Johnson CF, Macdonald HJ, Atkinson P, et al. Reviewing long-term 
antidepressants can reduce drug burden: a prospective observational cohort 
study. Br J Gen Pract 2012; DOI: 10.3399/bjgp12X658304.
4. Petty DR, House A, Knapp P, et al. Prevalence, duration and indications for 
prescribing of antidepressants in primary care. Age Ageing 2006; 35(5): 523–526.
5. Mojtabai R, Olfson M. National trends in long-term use of antidepressant 
medications: results from the US national health and nutrition examination 
survey. J Clin Psychiatry 2014; 75(2): 169–177.
6. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: 
United States, 2005–2008. NCHS data brief. 2011. http://www.cdc.gov/nchs/data/
databriefs/db76.pdf (accessed 8 Aug 2016).
7. Vektis. TherapietrouwMonitor. [Treatment Adherence Monitor]. 2015. http://
www.therapietrouwmonitor.nl/cijfers/depressie-0 (accessed 8 Aug 2016). 
8. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of 
Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment 
of anxiety, obsessive-compulsive and post-traumatic stress disorders — first 
revision. World J Biol Psychiatry 2008; 9(4): 248–312.
9. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological 
treatment of anxiety disorders, post-traumatic stress CG159 disorder and 
obsessive-compulsive disorder: a revision of the 2005 guidelines from the  
British Association for Psychopharmacology. J Psychopharmacol (Oxf) 2014; 
28(5): 403–439.
10. National Institute for Health and Care Excellence. Generalised anxiety disorder 
and panic disorder in adults: management. CG113. London: NICE, 2011. https://
www.nice.org.uk/guidance/cg113 (accessed 8 Aug 2016). 
11. National Institute for Health and Care Excellence. Social anxiety disorder: 
recognition, assessment and treatment. CG159. London: NICE, 2013. http://
www.nice.org.uk/guidance/cg159 (accessed 8 Aug 2016).
12. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological 
Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive 
disorders in primary care. World J Biol Psychiatry 2007; 8(2): 67–104. 
13. Cleare A, Pariante C, Young A, et al. Evidence-based guidelines for treating 
depressive disorders with antidepressants: a revision of the 2008  British 
Association for Psychopharmacology guidelines. J Psychopharmacol (Oxf) 2015; 
29(5): 459–525.
14. National Institute for Health and Care Excellence. Depression in adults: 
recognition and management. CG90. London: NICE, 2009. http://www.nice.org.
uk/guidance/cg90 (accessed 8 Aug 2016).
15. Piek E, van der Meer K, Nolen WA. Guideline recommendations for long-term 
treatment of depression with antidepressants in primary care — a critical 
review. Eur J Gen Pract 2010; 16(2): 106–112.
16. Bet PM, Hugtenburg JG, Penninx BWJH, Hoogendijk WJG. Side effects 
of antidepressants during long-term use in a naturalistic setting. Eur 
Neuropsychopharmacol 2013; 23(11): 1443–1451.
17. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in 
Europe 2010. Eur Neuropsychopharmacol 2011; 21(10): 718–779. 
18. Fineberg NA, Haddad PM, Carpenter L, et al. The size, burden and cost of 
disorders of the brain in the UK. J Psychopharmacol (Oxf) 2013; 27(9): 761–770. 
19. Leydon GM, Rodgers L, Kendrick T. A qualitative study of patient views on 
discontinuing long-term selective serotonin reuptake inhibitors. Fam Pract 
2007; 24(6): 570–575. 
20. Verbeek-Heida PM, Mathot EF. Better safe than sorry — why patients prefer to 
stop using selective serotonin reuptake inhibitor (SSRI) antidepressants but are 
afraid to do so: results of a qualitative study. Chronic Illn 2006; 2(2): 133–142. 
21. Muntingh A, Hermens M, Franx G, et al. Werkelijke en wenselijke eerstelijns 
depressiezorg: resultaten van een verkennend onderzoek. Trendrapportage GGZ 
2012 Deel 3B. [Actual and desired primary care of depression: results of an 
exploratory study. Trend report GGZ 2012 Part 3B]. 2012. https://www.trimbos.
nl/producten-en-diensten/webwinkel/product/?prod=AF1203 (accessed 28 Jun 
2016).
22. Glaser BG, Strauss AL. Discovery of grounded theory: strategies for qualitative 
research. New Brunswick, NJ: Aldine, 1967.
23. Hanlin CE, Bess K, Conway P, et al. Community psychology. In: Willig C, 
Stainton Rogers W, eds. The Sage handbook of qualitative research in 
psychology. Los Angeles, CA: Sage, 2008: 524–540.
24. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative 
research (COREQ): a 32-item checklist for interviews and focus groups. Int J 
Qual Health Care 2007; 19(6): 349–357. 
25. van Damme R, van den Bosch W, Doveren M, Marks A. Veranderingen in 
de huisartsenpraktijk vragen om managementondersteuning (Changes in 
general practices require management support). 2009. https://www.henw.org/
archief/volledig/id3300-veranderingen-in-de-huisartsenpraktijk-vragen-om-
managementondersteuning.html (accessed 8 Aug 2016).
26. Iancu SC, Batelaan NM, Zweekhorst MBM, et al. Trajectories of functioning 
after remission from anxiety disorders: 2-year course and outcome predictors. 
Psychol Med 2014; 44(3): 593–605. 
27. van Rijswijk E, van Hout H, van de Lisdonk E, et al. Barriers in recognising, 
diagnosing and managing depressive and anxiety disorders as experienced by 
family physicians; a focus group study. BMC Fam Pract 2009; 10(1): 52. 
28. Ambresin G, Palmer V, Densley K, et al. What factors influence long-term 
antidepressant use in primary care? Findings from the Australian diamond 
cohort study. J Affect Disord 2015; 176: 125–132. 
29. Wildeboer R, van der Hoek L, Verhaak PF. Use of GP services 5 years after an 
episode of mental illness: case-control study using electronic records. Br J Gen 
Pract 2016; DOI: 10.3399/bjgp16X684973.
30. van Geffen ECG, Hermsen JHCM, Heerdink ER, et al. The decision to continue 
or discontinue treatment: experiences and beliefs of users of selective 
serotonin-reuptake inhibitors in the initial months — a qualitative study. Res Soc 
Adm Pharm 2011; 7(2): 134–150. 
31. Ketelaar MH, Grundmeijer HGLM. SSRI’s in de Nederlandse huisartsenpraktijk. 
[In Dutch]. Huisarts En Wet 2010; 53(6): 302–305. 
32. Figueroa CA, Ruhé HG, Koeter MW, et al. Cognitive reactivity versus 
dysfunctional cognitions and the prediction of relapse in recurrent major 
depressive disorder. J Clin Psychiatry 2015; 76(10): e1306–e1312. 
33. Dickinson R, Knapp P, House AO, et al. Long-term prescribing of 
antidepressants in the older population: a qualitative study. Br J Gen Pract 2010; 
DOI: 10.3399/bjgp10X483913.
British Journal of General Practice, October 2016  e715
Appendix 1. Topic list in patient interviews
The topic list provided guidance to the interviews. Not all items were necessarily included in all interviews; this depended on the information retrieved during the 
interview. Questions in italic were included in the topic list in the course of the study. 
Continuation or discontinuation of antidepressants
1. Did you previously discontinue your medication?
a. Reason?
2. What are your experiences with discontinuation?
a. Do these experiences affect your decision to continue or discontinue?
3. Are you currently considering discontinuation?
a. Why/why not?
b. Have you any expectations of consequences following discontinuation?
c. To what extent do you think you can cope with your anxiety/depressive disorder without medication?
i. To what extent does this influence your decision to continue or discontinue?
d. Have you anticipated any expected benefits from discontinuation?
e. Which role do side effects play in your decision whether or not to continue or discontinue antidepressants?
i. Which side effects?
ii. Did the patient consider discontinuation due to the mentioned side effects?
f. To what extent do you worry about:
i. Discontinuation symptoms?
ii. Relapse?
1. Is this fear of relapse realistic?
iii. The antidepressant not being effective anymore when restarting it?
1. Is that worry related to the type of antidepressant or the dose?
2. Has this something to do with the number of attempts you made before an effective antidepressant was found?
a. If so, which antidepressants were tried, and in what dose?
3. Has this something to do with the disorder for which the antidepressant was prescribed, or with the course of the disorder (recurrent or first episode)?
4. To what extent does the patient consider discontinuation in the future?
a. If discontinuation is considered:
i. What do you need for discontinuation/which conditions apply to discontinuation?
ii. What would be a suitable moment to discontinue?
1. How soon would you like to discontinue your antidepressant?
b. If discontinuation is not considered:
i. When is it responsible to continue antidepressants?
1. To what extent did/do you accept that you will be taking antidepressants without an endpoint? Why?
GP–patient relationship
5. Have you felt restrained in any way discussing discontinuation of antidepressants with your GP? Why?
a. Was your GP previously involved when you discontinued your medication?
b. Who took the initiative to start discussing discontinuation? What do you think about that?
6. If/when you would discontinue again, would you involve your GP?
a. Why/why not?
b. In your opinion, how important is the role of the GP for discontinuation?
i. Which aspects do you consider important?
ii. Is this role also crucial for discontinuation?
7. To what extent do you think that your GP has sufficient knowledge and experience to advise you well and to help with discontinuing antidepressants?
8. To what extent do you think you are responsible for the contact between you and your GP regarding your antidepressant use?
a. If there is little contact between the GP and patient: do you think that this could result in long-term use?
9. What does your GP think about your use of antidepressants (to either continue or discontinue)? Does this affect the choices you make?
Influences on the choice to continue or discontinue
10. What do your family/partner/friends think about your antidepressant use (either to continue or discontinue)?
a. Does this affect your choice whether or not to continue or discontinue?
11. Which role does the current organisation of the Dutch healthcare system play in your decision whether or not to continue or discontinue antidepressants?
a. How are things organised in the GP practice you attend?
b. What could be improved?
c. Would there be something you would like to see changed in the Dutch healthcare system that would facilitate discontinuation for you?
12. Which role do news reports in the media play in your decision whether or not to continue or discontinue antidepressants?
13. Are there any other factors that play a role in your decision whether or not to continue or discontinue antidepressants?
a. Which factors facilitate discontinuation?
b. Which factors hinder discontinuation?
14. Do you notice/have you noticed any taboo/stigma regarding antidepressants, depressive disorder, and anxiety disorder?
a. Does this influence your use of antidepressants?
b. What do you yourself think about antidepressants?
.... continued
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Psychological support
15. How much distress did the patient experience before they started with antidepressants?
16. What do you think about psychological treatment in comparison with pharmacological treatment (medication)?
a. What else had previously been tried?
i. Which therapy?
1. From which therapy did you benefit most?
b. How does this affect your choice whether or not to continue or discontinue antidepressants?
17. Is psychological care a decent/viable alternative to medication?
18. What are the advantages and disadvantages of antidepressant use?
19. If applicable: On which grounds do you base that your complaints/symptoms are chronic?
a. On what do you base the view that your complaints are of a biological origin and that psychological care is not helpful to you?
b. Are you, because you are willing to accept psychological care, more likely to discontinue your use of antidepressants?
Perception of anxiety/depressive disorder: how does this affect antidepressant use?
20. What do you think is the cause of your depressive disorder? Does the reason for your depression influence your use/acceptance of the medication?
21. To what extent do you see depression as something more biological or more psychological?
a. Biological: is it easier to talk about it? (Because the cause is ‘clear’?)
i. Why/why not?
ii. Does this affect your choice whether or not to continue or discontinue?
22. Do you view yourself differently since you started using antidepressants?
a. Why? And in what ways?
23. Does the fact that you have been using antidepressants for such a long time make it more difficult to discontinue?
a. Has this changed since the first time you discontinued?
Other
24. If a patient came from specialised care:
a. How many therapists did the patient have?
b. How was the transition from the psychiatrist to the GP?
c. What does the patient mean by a ‘good transition’?
25. Would the patient like to discontinue? If so, would they be prepared to participate in research investigating predictors of relapse? What considerations play a role?
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Appendix 2. Topic list in GP interviews
The topic list provided guidance to the interviews. Not all items were necessarily included; this depended on the information being retrieved during the interview. 
Questions in italic were included in the topic list in the course of the study and questions with an ‘*’ were of particular relevance to the patient–GP dyads.
Continuation or discontinuation of antidepressants
1. *Do you ever advise patients who have been using antidepressants long-term to discontinue?
a. To what extent do you think that the patient should continue or discontinue?
b. How does this work in practice?
c. How do patients respond?
d. What reasons do patients have to continue or discontinue antidepressants?
e. What are the advantages and disadvantages of antidepressant use?
f. What are the advantages and disadvantages of antidepressant discontinuation?
2. *When would you like to discontinue antidepressants with this patient?
a. Is there a suitable moment in the future?
b. What would be a suitable moment (definition)?
3. *What are your previous experiences with patients discontinuing antidepressants?
a. Do those experiences influence current decisions on whether or not to continue or discontinue antidepressants?
4. *Expectations GPs may have of possible consequences for patients following discontinuation:
a. To what extent do you think patients can cope with their anxiety/depressive disorder without medication?
i. To what extent does this influence your decision to continue or discontinue?
b. Which role do side effects play in your decision whether or not to continue or discontinue antidepressants?
i. What side effects are mentioned by patients?
ii. Do patients consider discontinuation due to the mentioned side effects?
c. To what extent do you worry about:
i. Discontinuation symptoms?
ii. Relapse?
1. To what extent do you think the patient who expects to relapse will actually relapse?
2. Is this fear of relapse realistic?
3.  To what extent do you think that people who think that they can manage without antidepressants are less likely to relapse because they have faith in their own 
ability to function without medication?
4. Do you use different policies for both groups of patients?
iii. Whether the antidepressant is no longer effective when restarting?
1. Is that related to the type of antidepressant, or the dose?
2. Has this something to do with the number of attempts before an effective antidepressant was found for the patient?
a. If so, which antidepressants were tried, and in what dose?
3. Has this something to do with the disorder for which the antidepressant was prescribed, or with the course of the disorder (recurrent or first episode)?
5. *In your own words what would you need in order to be able to discontinue with more patients/which conditions apply?
a. To what extent does the quality of the contact with the patient play a role?
6. Placebo effect: Is there a group of people for whom you think that the medication is not effective, but functions as a placebo?
a. What do these patients need to discontinue?
GP–patient relationship
7. *Do patients frequently indicate that they want to discontinue or that they want to discuss the decision whether or not to continue or discontinue?
a. How do you generally respond to these questions?
8. *Who tends to start the discussion about discontinuation more frequently, you or the patient?
9. *In your opinion, how important is the role of the GP regarding discontinuation?
a. What aspects do you consider important?
b. Is this role also crucial for discontinuation?
10. *Do you feel capable to discontinue antidepressants?
a. To what extent do you think you have sufficient knowledge and experience to advise patients correctly and to help them with discontinuing antidepressants?
b. If not, which additional knowledge do you need?
11. *To what extent do you think the patient is responsible for contact between you and the patient regarding use of antidepressants?
a. Who do you think should take the initiative to discuss discontinuing antidepressants?
i. Has this changed over the years?
b. If there is little contact between the patient and GP, do you think that this could result in long-term use of antidepressants?
12. Do you experience it as a burden when patients return to you after they have relapsed following discontinuation?
a. Is this a reason to not discontinue antidepressants (too burdensome for office hours)?
13. Emotional involvement:
a. Do you mind personally when patients relapse?
b. Does this affect the contact you have with patients about antidepressants?
Influences on the choice to continue or discontinue
14. To what extent do you have the impression that discontinuation is more difficult in patients with a personality disorder?
a. If so, what makes it more difficult?
15. To what extent are the time until antidepressants are effective and the time it takes to discontinue, of influence on discontinuation?
16. Are there any other factors that play a role in the decision whether or not to continue or discontinue antidepressants?
a. The (social) environment?
b. The role of current organisation of the Dutch healthcare system?
i. Does It frequently happen that patients had previous multiple therapists in specialised care?
c. The media?
d. The role of healthcare insurance?
e. The role of the government?
.... continued
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Psychological support
17. What is your view on psychological treatment?
a. How does your view affect your decision whether or not to continue or discontinue antidepressants?
b. If GP is enthusiastic about psychological treatment, why are you still prescribing medication for depression/anxiety disorders?
18. What is your view on pharmacological treatment/antidepressants?
a. How does your view affect your decision whether or not to continue or discontinue antidepressants?
19. To what extent are patients willing to attend psychotherapy also more likely to discontinue?
a. Are you, because you are in favour of psychological care, more likely to discontinue?
20. Do you provide, in your own opinion, relatively little, or a lot of mental health care?
a. Reason?
21. If applicable: On which grounds do you base that your complaints/symptoms are chronic?
Perceptions
22. What is your view on the pathophysiology of depression?
a. How does this affect your policies regarding the discontinuation of antidepressants?
Other
23. To what extent do you use the treatment guidelines when treating anxiety disorders and/or depressive disorders?
a. What do you think about the treatment guidelines?
24.  Could the GP make an estimate of the number of people they saw in the past month presenting with depressive and/or anxiety symptoms, and how many of 
those received a prescription for antidepressants?
25. *Diagnosis of patient? (This question verified with the GP the diagnosis for which the patient was prescribed antidepressants.)
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